熱門資訊> 正文
Altimune发布MASH额外2期培维杜肽数据
2025-11-11 23:04
- Additional data from the phase 2b trial of Altimmune's (ALT) pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH) some improvements in the liver condition over 24 weeks of treatment.
- The trial has two primary endpoints, MASH resolution without worsening of fibrosis and fibrosis improvement without worsening of MASH. For the first endpoint, the figures were, respectively, 58% and 52%, for the 1.2 mg and 1.8 mg (20% placebo) doses, and 33% and 36% for the second (28% placebo).
- The latest information follows topline results of the dual glucagon and GLP-1 receptor agonist released in June 2025. However, the company's shares dropped precipitously then as the Street viewed the results as mixed.
More on Altimmune
- Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript
- Altimmune: Competitor Buyouts Plus Regulatory And Clinical Progress
- Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
- Altimmune outlines flexible Phase III design and regulatory milestones while strengthening leadership
- Altimmune Q3 2025 Earnings Preview
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
